Accueil   Diary - News   All news Alaxia joins EU consortium to combat drug-resistant lung infections

Alaxia joins EU consortium to combat drug-resistant lung infections

 

Partnership in iABC project will accelerate Alaxia’s development of promising
antimicrobial therapy for cystic fibrosis

 

 

Lyon, France, October 23, 2019 – Alaxia, an affiliate of the Stragen Healthcare Group developing therapeutic solutions for respiratory diseases, today announces it has joined the iABC (inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis) consortium as a partner. The iABC project, consisting of 22 partners in eight European countries, aims to advance the development of two inhaled antimicrobials for patients with cystic fibrosis and bronchiectasis. These patients are at particular risk of respiratory infections, frequently caused by drug-resistant microbes that reduce life expectancy.

 


Through the consortium, Alaxia will accelerate development of its antibacterial candidate for cystic fibrosis, ALX-009. Alaxia will gain access to all patient and clinical trial networks. It will also have access to expertise on inhaled antimicrobials from iABC members, as well as member support in clinical trials and patient recruitment.

 

 

 

Read the press release 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree